Amneal Pharmaceuticals (AMRX) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Amneal Pharmaceuticals (NASDAQ: AMRX) recently:

• 11/10/2026 – Amneal Pharmaceuticals was downgraded by Weiss Ratings from “buy (b)” to “hold (c+)”.
• 11/5/2026 – Amneal Pharmaceuticals had its price target raised by Leerink Partners from $23.00 to $25.00. They now have an “outperform” rating on the stock.
• 11/4/2026 – Amneal Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler. They now have a $21.00 price target on the stock.
• 11/4/2026 – Amneal Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $24.00 to $25.00. They now have an “overweight” rating on the stock.
• 10/29/2026 – Amneal Pharmaceuticals had its “buy” rating reaffirmed by The Goldman Sachs Group. They now have a $24.00 price target on the stock.
• 10/26/2026 – Amneal Pharmaceuticals was upgraded by Zacks Research from “strong sell” to “hold”.
• 10/22/2026 – Amneal Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $22.00 to $24.00. They now have an “overweight” rating on the stock.
• 10/8/2026 – Amneal Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/6/2026 – Amneal Pharmaceuticals was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/1/2026 – Amneal Pharmaceuticals had its “buy” rating reaffirmed by UBS Group.
• 9/23/2026 – Amneal Pharmaceuticals is now covered by Oppenheimer. They set an “outperform” rating and a $27.00 price target on the stock.
• 9/17/2026 – Amneal Pharmaceuticals had its price target raised by Barclays from $16.00 to $20.00. They now have an “overweight” rating on the stock.

Amneal Pharmaceuticals Trading Up 0.5%

Shares of AMRX stock opened at $21.38 on Wednesday. The stock has a market cap of $6.83 billion, a price-to-earnings ratio of 50.90, a price-to-earnings-growth ratio of 2.42 and a beta of 1.24. The company has a quick ratio of 1.24, a current ratio of 1.87 and a debt-to-equity ratio of 5.61. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $11.39 and a fifty-two week high of $21.68. The firm’s 50 day moving average price is $19.49 and its two-hundred day moving average price is $15.99.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.03. Amneal Pharmaceuticals had a net margin of 4.17% and a return on equity of 283.50%. The company had revenue of $862.68 million during the quarter. On average, analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.98 EPS for the current year.

Insiders Place Their Bets

In related news, Director John Kiely sold 50,000 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the sale, the director directly owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.